Cite
Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.
MLA
Moots, Robert J., et al. “Reduction of Direct and Indirect Costs in Patients with AS Receiving Etanercept: Results from an Open-Label 36-Week Extension of the ASCEND Study in Four European Countries.” Rheumatology, vol. 51, no. 2, Feb. 2012, pp. 393–96. EBSCOhost, https://doi.org/10.1093/rheumatology/ker404.
APA
Moots, R. J., Ostor, A. J. K., Loft, A. G. R., Järvinen, P., Larsson, P., Ekelund, M., Reynolds, A., Kielar, D., Lindkvist, R.-M., & Qvitzau, S. (2012). Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries. Rheumatology, 51(2), 393–396. https://doi.org/10.1093/rheumatology/ker404
Chicago
Moots, Robert J., Andrew J. K. Ostor, Anne G. R. Loft, Pentti Järvinen, Per Larsson, Mats Ekelund, Alan Reynolds, Danuta Kielar, Rose-Marie Lindkvist, and Susanne Qvitzau. 2012. “Reduction of Direct and Indirect Costs in Patients with AS Receiving Etanercept: Results from an Open-Label 36-Week Extension of the ASCEND Study in Four European Countries.” Rheumatology 51 (2): 393–96. doi:10.1093/rheumatology/ker404.